Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. Keeping that in mind, here is one value stock trading at a big discount to its intrinsic value and two facing an uphill battle.
Two Value Stocks to Sell:
Park-Ohio (PKOH)
Forward P/E Ratio: 11.3x
Based in Cleveland, Park-Ohio (NASDAQ: PKOH) provides supply chain management services, capital equipment, and manufactured components.
Why Does PKOH Give Us Pause?
- Annual sales declines of 1.2% for the past two years show its products and services struggled to connect with the market during this cycle
- Performance over the past two years was negatively impacted by new share issuances as its earnings per share dropped by 8.3% annually, worse than its revenue
- Cash-burning history makes us doubt the long-term viability of its business model
At $38.35 per share, Park-Ohio trades at 11.3x forward P/E. Dive into our free research report to see why there are better opportunities than PKOH.
Integra LifeSciences (IART)
Forward P/E Ratio: 7.2x
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Do We Think IART Will Underperform?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 2.4% annually while its revenue grew
- 5× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Integra LifeSciences’s stock price of $17.87 implies a valuation ratio of 7.2x forward P/E. Read our free research report to see why you should think twice about including IART in your portfolio.
One Value Stock to Watch:
Magnolia Oil & Gas (MGY)
Forward P/E Ratio: 8.9x
Operating over 600,000 net acres primarily in two distinct South Texas regions, Magnolia Oil & Gas (NYSE: MGY) drills and produces oil, natural gas, and natural gas liquids from South Texas formations.
Why Are We Fans of MGY?
- Annual revenue growth of 18.7% over the past five years was outstanding, reflecting market share gains this cycle
- Highly-profitable operating model results in strong unit economics and a best-in-class gross margin of 84.6%
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
Magnolia Oil & Gas is trading at $27.20 per share, or 8.9x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
